Editorial
HSP90 inhibitors for high-grade glioma treatment
Translational Cancer Research
2018;
7
(Suppl 1)
:S1-S2
.
(06 February 2018)
Editorial on MSKCC prospective validation study of ACOSOG Z0011 Trial—what have we learned?
Translational Cancer Research
2018;
7
(Suppl 1)
:S3-S5
.
(06 February 2018)
Does ipilimumab show an increased clinical benefit when combined in sequence with chemotherapy?
Translational Cancer Research
2018;
7
(Suppl 1)
:S6-S9
.
(06 February 2018)
Novel mechanisms of chemoresistance by Fusobacterium nucleatum involve not so novel pathways of microRNAs and autophagy
Translational Cancer Research
2018;
7
(Suppl 1)
:S10-S15
.
(06 February 2018)
Smooth sailing for immunotherapy for unresectable stage III nonsmall cell lung cancer: the PACIFIC study
Translational Cancer Research
2018;
7
(Suppl 1)
:S16-S20
.
(06 February 2018)
Intratumoral bacteria as potential contributor of gemcitabine resistance
Translational Cancer Research
2018;
7
(Suppl 1)
:S21-S23
.
(06 February 2018)
Prostate-specific membrane antigen and renal cell carcinoma: a new diagnostic and therapeutic target?
Translational Cancer Research
2018;
7
(Suppl 1)
:S24-S25
.
(06 February 2018)
Icotinib improves progression free survival in epidermal growth factor receptor positive non-small cell lung cancer patients
Translational Cancer Research
2018;
7
(Suppl 1)
:S26-S30
.
(06 February 2018)
Oncogenic insult to the brain: sox proteins rise to the occasion
Translational Cancer Research
2018;
7
(Suppl 1)
:S31-S33
.
(06 February 2018)
Oxygen starvation during T cell priming boosts cancer-killing potential
Translational Cancer Research
2018;
7
(Suppl 1)
:S34-S37
.
(06 February 2018)
A circRNA/miR axis contributes to hypoxia-induced cardiomyocyte death
Translational Cancer Research
2018;
7
(Suppl 1)
:S38-S40
.
(06 February 2018)
Checkpoint inhibitors after chemoradiation: is it ready for prime time?
Translational Cancer Research
2018;
7
(Suppl 1)
:S41-S43
.
(06 February 2018)
CircMTO1: a novel regulator of hepatocellular carcinoma progression
Translational Cancer Research
2018;
7
(Suppl 1)
:S44-S46
.
(06 February 2018)
Genomic scores are independent of disease volume in men with favorable risk prostate cancer—implications for choosing men for active surveillance
Translational Cancer Research
2018;
7
(Suppl 1)
:S47-S49
.
(06 February 2018)
Circular RNA: non-coding RNA with emerging roles in stem cell differentiation
Translational Cancer Research
2018;
7
(Suppl 1)
:S50-S52
.
(06 February 2018)
New hope for advanced nasopharyngeal cancer—an Epstein-Barr virus-driven endemic malignancy?
Translational Cancer Research
2018;
7
(Suppl 1)
:S53-S57
.
(06 February 2018)
Editorial on “PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis”
Translational Cancer Research
2018;
7
(Suppl 1)
:S58-S60
.
(06 February 2018)
CRISPR-based genetic interaction maps inform therapeutic strategies in cancer
Translational Cancer Research
2018;
7
(Suppl 1)
:S61-S67
.
(06 February 2018)
A novel window opened: EBV-driven enhancer-promoter loops in lymphocytic immortalization
Translational Cancer Research
2018;
7
(Suppl 1)
:S68-S70
.
(06 February 2018)
S100A4, a key factor in glioblastoma biology
Translational Cancer Research
2018;
7
(Suppl 1)
:S71-S73
.
(06 February 2018)
Editorial on “Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial”
Translational Cancer Research
2018;
7
(Suppl 1)
:S74-S76
.
(06 February 2018)
Circular RNA shifts the miRNA binding panel and takes a role in hepatocellular carcinoma progression
Translational Cancer Research
2018;
7
(Suppl 1)
:S77-S80
.
(06 February 2018)
Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents
Translational Cancer Research
2018;
7
(Suppl 1)
:S81-S84
.
(06 February 2018)
The importance of galectin-3 as a novel target for lung cancer patients harboring KRAS mutation
Translational Cancer Research
2018;
7
(Suppl 1)
:S85-S88
.
(06 February 2018)
Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
Translational Cancer Research
2018;
7
(Suppl 1)
:S89-S93
.
(06 February 2018)
Lymph node positive prostate cancer: the evolving role of adjuvant therapy
Translational Cancer Research
2018;
7
(Suppl 1)
:S94-S95
.
(06 February 2018)
Letter to the Editors
Multiscale modeling of glioblastoma
Translational Cancer Research
2018;
7
(Suppl 1)
:S96-S98
.
(06 February 2018)
Disclosure:
This supplement was published without any sponsorship or funding.
